Supporting Information

Figure S1. The dose response curve of compounds 1–3 and cisplatin at each tested cell lines.




Figure S1. Cont.






Figure S1. Cont.








Figure S2. ¹H-NMR (600 Hz, CDCl₃) spectrum of the new compound acerolanin **A**.




Figure S3. ¹³C-NMR (125 MHz, CDCl₃) spectrum of the new compound acerolanin **A**.




Figure S4. The HMBC spectrum of the new compound acerolanin **A**.




Figure S5. The HSQC spectrum of the new compound acerolanin A.




Figure S6. ¹H-¹H COSY spectrum of the new compound acerolanin **A**.




Figure S7. ¹H-NMR (600 MHz, CDCl₃) spectrum of the new compound acerolanin **B**.




Figure S8. ¹³C-NMR (125 MHz, CDCl₃) spectrum of the new compound acerolanin **B**.




Figure S9. The HMBC spectrum of the new compound acerolanin **B**.




Figure S10. The HSQC spectrum of the new compound acerolanin B.




Figure S11. ¹H-¹H COSY spectrum of the new compound acerolanin **B**.




Figure S12. ¹H-NMR (600 MHz, CDCl₃) spectrum of the new compound acerolanin **C**.




Figure S13. ¹³C-NMR (125 MHz, CDCl₃) spectrum of the new compound acerolanin C.






Figure S14. The HMBC spectrum of the new compound acerolanin C.








Figure S16. ¹H-¹H COSY spectrum of the new compound acerolanin **C**.

